Skip to main content
OpenTrials
Completed

NCT Number: NCT01187862

Pharmacokinetic Study to Investigate Low-dose Combinations of a Cocktail of Seven Drugs for Simultaneous Phenotyping of Cytochromes

The purpose of this study is to assess whether a cocktail of seven approved drugs (so-called "Basel cocktail") can be used for simultaneous phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

University Hospital

Basel, 4031, Switzerland

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent
  • Male aged between 18 and 45 years
  • No clinically significant findings on the physical examination
  • Body mass index (BMI) between 18 and 28 kg/m2
  • Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90 mmHg, and heart rate (HR) 45-90 bpm (inclusive)
  • 12-lead electrocardiogram (ECG) without clinically relevant abnormalities
  • Hematology and clinical chemistry results not deviating from the normal range to a clinically relevant extent
  • Negative results from urine drug screen
  • Ability to communicate well with the investigator and to understand and comply with the requirements of the study

Exclusion criteria

  • Known hypersensitivity to any excipients of the drug formulations
  • Treatment with another investigational drug within 30 days prior to screening
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening
  • Excessive caffeine consumption, defined as mor than 800 mg per day
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug
  • Smoking within the last 3 months prior to screening
  • Previous treatment with any prescribed or OTC medications (including herbal medicines such as St John's Wort) within 2 weeks prior to screening
  • Loss of 250 ml or more of blood within 3 months prior to screening
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol
  • Legal incapacity or limited legal capacity at screening

Treatment and study plan

caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam

Drug

Primary outcomes

  1. Assessment of phenotyping measures of seven drugs used as a cocktail

Sponsors and collaborators

Lead sponsor

University Hospital, Basel, Switzerland

Other

Registry information

Official study title

Single-center, Randomized, Five-way Crossover Study to Investigate Low-dose Combinations of Caffeine, Efavirenz, Losartan, Omeprazole, Metoprolol, Chlorzoxazone and Midazolam ("Basel Cocktail") for Simultaneous Phenotyping of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in Healthy Male Subjects

Important dates

Study start
2010
Primary completion
2011
First posted
Aug 24, 2010
Registry last updated
Apr 17, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.